News & publications

Avista Capital Partners invests in OptiNose - June 7th, 2010 09.06.2010

New data on highly effective treatment for chronic rhinosinusitis with nasal polyps 04.12.2009

OptiNose presents new data on highly effective treatment for chronic rhinosinusitis 17.04.2009

17 April 2009 - Upcoming Event - Rhinology World 2009 Presentation 26.03.2009

1 April 2009 - Upcoming Event - Nasal Drug Delivery Conference Presentation 26.03.2009

OptiNose Presents Data On Highly Effective Nasal Polyp Treatment 19.09.2008

20 September 2008 - Upcoming Event: Amercian Rhinology Society Presentation 18.07.2008

American Headache Society - Phase II Migraine (poster presentation) 29.06.2008

OptiNose Presents Data on Highly Effective Migraine Treatment 29.06.2008

American Academy of Neurology - Phase I Migraine (poster presentation) 18.04.2008

OptiNose Nasal Delivery of Sumatriptan Proves as Effective as Subcutaneous Injection 18.04.2008

Phase I Human Insulin Data 23.03.2008

New Phase II Data for Nasal Polyposis 05.12.2007

OptiNose Completes Phase II Study in Migraine 05.11.2007

OptiNose Initiates Phase II Study in Chronic Rhinosinusitis 05.10.2007

OptiNose Completes Phase I Study with Triptan 20.12.2006

OptiNose Completes Phase I Study with Topical Steroid 23.10.2006

Abstract of Article in The Laryngoscope (67Kb Pdf) 20.03.2006
Compared with a spray pump, the novel breath actuated bidirectional device provides significantly larger deposition in the clinically important regions beyond the nasal valve and reduced anterior deposition. These striking differences provide new opportunities for improved therapy of chronic rhinosinusitis and polyposis as well as extended use of the nose for delivery of drugs from the nose into the brain. Please contact us for reprint of the full article.

Article in ONdrugDelivery (1 MB pdf) 10.10.2005
Nasal drug delivery is already a thriving market but there is still a wide gap between what has been achieved in the past and what could be achieved were the full potential of this highly attractive administration route released. This article describes a technological breakthrough by OptiNose that has allowed the company to make that hitherto elusive step of achieving truly optimal nasal drug delivery. Compiled by ONdrugDelivery on behalf of OptiNose.

Abstract of Article in Journal of Aerosol Medicine (66Kb Pdf) 03.11.2004
Bi-Directional Nasal Delivery of Aerosols Can Prevent Lung Deposition Journal of Aerosol Medicine, 1 September 2004, vol. 17, no. 3, pp. 249-259(11)

Bi-directional nasal drug delivery (1 MB pdf) 10.07.2004
A new concept in nasal drug delivery looks set to transform the delivery efficiency of nasal spray products. A revolutionary new technology is expected to have a dramatic impact on the delivery of drugs via the nasal route. Traditionally, the development of nasal spray products has been faced with a major dilemma: on the one hand, nasal delivery can be improved by using smaller particles, but on the other, this has to be balanced against the increased risk of drug being inhaled into the lungs. A new concept, bi-directional drug delivery, addresses this dilemma by isolating the nasal circuit from the lungs – enabling particle size, flow rate and direction to be optimised.

Article in Pharmaceutical Technology (link) 10.09.2004
Traditional nasal spray pumps face a common challenge: they cannot ef f i c i en t ly del iver drug to the regions of the nasal passages where diseases originate. To address this problem, OptiNose AS (Oslo, Norway, www. optinose.no) has developed a patented bi-directional delivery system that can target the olfactory region. The “OptiMist,”a single - dose device .... (read more)

Who Nose How Far Nasal Delivery Can Go? (0,5 MB pdf) 07.10.2003
Nasal delivery has traditionally been restricted to topically acting substances used to treat the common cold and nasal allergies. Recently, however, there has been increased interest in the nose as an alternative to oral delivery and injection for many systemic drugs and vaccines. The highly vascularised and immunogenic nasal mucosa offers potential advantages in terms of quick action, improved bio-availability and patient compliance as well as improved immune response for vaccines. European Pharmaceutical Contractor, Autum 2003

Nothing to Sneeze At (1,3 MB pdf) 29.01.2003
Often overlooked and long neglected, the nose has become one of the most viable drug delivery pathways for treating everything from the flu to erectile dysfunction. The portal to our blood system is how nasal drug delivery experts view the nose. With the continuous development of more potent and complex molecules and the imminent expiration of many patents for major brands, novel delivery systems offer opportunities for developmental and marketed compounds alike. Nasal delivery is ideal for potent drugs that are to be delivered in small doses, as low as tens of milligrams. Copyrighted material, reprinted with permission from Pharmaceutical Formulation & Q u a l i t y Magazine, June/July 2002 issue. For more information, visit www.pharmaquality.com. Reprint of full format article in pdf-format. Compiled by CINDY H.DUBIN.

Nasal delivery of vaccines (pdf) 29.01.2003
Recently nasal delivery of vaccines has emerged as an attractive alternative to injection. Nasal vaccination elicits a local immune response and protection in addition to the systemic response. The mucosal immune response is rapid and nasal vaccines may induce protection in distant mucosal sites in the gut and uro-gentital tract as well. Proper formulation and adequate distribution to the nasal mucosa are essential for the efficiency and safety of mucosal vaccines. The complex nasal geometry represents a major challenge for efficient intranasal vaccination. Current delivery devices may prove inadequate to meet the future requirements for safe and reliable nasal vaccination. With permission from Pharmaceutical Manufacturing and Packing Sourcer